AP20 Rec'd PCT/PTO 01 JUN 2006

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jose Luis Castro Pineiro

Int'l Appln.
No.: PCT/GB2004/005234

Int'l Date
Filed: 18 December 2004 (12/18/2004)

Serial No.: (To be assigned) Case No.: T1650P

Filed : June 1, 2006

For : TREATMENT FOR ALZHEIMER'S DISEASE AND

RELATED CONDITIONS

Commissioner for Patents

Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE


EXPRESS MAIL NO. EV66060F126US

THEREBY CERTIFY THAT THIS CORRESPONDENCE IS

HEREBY CERTIFY THAT THIS CURRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE BATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, PO. BOX 2460,
ALEXANDRIA, VIRGINIA 223/13/1450.

ALEXANDRIA, VIRGINIA 2237 MAILED BY AVIV VI

DATE



This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

I Frie Thiss

keg. No. 35,382

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3904

Date: June 1, 2006

					FAIGH AND TRANSPORT OTHER, U.S DEFARTMENT OF COMMERCE		
s	Substitute for form 1449A/PTO INFORMATION DISCLOSURE			COMPLETE IF KNOWN			
				Application Number	10/501291		
	STATEMENT B	37 A D	DI ICANIT	Filing Date			
2	SIAIEWENI D	Y AP	PLICANI	First Named Inventor	Jose Luis Castro Pineiro		
		-4		Group Art Unit 20 P	C'OPCT/PTO 01 JUN 2006		
(use as many sheets as necessary)				Examiner Name			
Sheet	1	of	2	Attorney Docket Number	T1650P		
							

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code (known)		Date of Publication of Cited Document MM-DD-YYYY	
		US 5767124		Draper et al	06/16/1998	
			<u> </u>			

FOREIGN PATENT DOCUMENTS						
Cite No.	Office		Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
		WO 2004/087157		Merck Sharp & Dohme Limited	10/14/1004	
		EP 1258250		Kaken Pharmaceutical Co., Ltd.	11/20/2002	
		·				
				<u> </u>		
	ļ				-	
			Foreign Patent Document No. Office Number	Foreign Patent Document	Cite No. Office Number Kind Code (if known) WO 2004/087157 Merck Sharp & Dohme Limited	

Examiner Signature Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	- Substitute for form 1449B/PTO INFORMATION DISCLOSURE			COMPLETE IF KNOWN			
				Application Number	10/581291		
- STATEMENT BY APPLICANT				Filing Date			
	SIAIEMENIB	r Ar	PLICANI	First Named Inventor	Jose Luis Castro Pineiro		
			,	Group Art United	EGRETING OF HER 2006		
	(use as many shee	s as n	ecessary)	Examiner Name			
Sheet	2	of	2	Attorney Docket Number	T1650P		

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
		Smith R. G.: "The aging process: where are the drug opportunities?" Current Opinion in Chemical Biology, vol. 4, no. 4, August 2000 (2000-08) pp. 371-376.				
		Dalrymple S. A.: "P38 Mitogen Activated Protein Kinase As A Therapeutic Target For Alzheimer's Disease", Journal of Molecular Neuroscience, vol. 19, no. 3, December 2002, pp. 295-299.				
		Ankersen M. et al: "Growth hormone secretagogues: recent advances and applications", Drug Discovery Today, Elsevier Science Ltd. vol. 4, no. 11, 1999, pp. 497-506.				
		Merriam, G.R. et al.: "Growth hormone-releasing hormone and growth hormone secretagogues in normal aging" vol. 22, no. 1, October 2003, pp. 41-48.				

Examiner		Date	
Signature		Considered	1
	· ·		1

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.